Ocumension Therapeutics (SEHK:1477) - Hisse Senedi Fiyatı, Haberler ve Analizler

1477 Stoklara Genel Bakış

Ocumension Therapeutics, iştirakleri ile birlikte Çin Halk Cumhuriyeti'nde bir oftalmik ilaç platformu şirketi olarak faaliyet göstermektedir. Daha fazla detay

1477 temel anali̇z
Kar Tanesi Skoru
Değerleme	3/6
Gelecekteki Büyüme	5/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 59.4% daha düşük bir oranda işlem görüyor

Kazançların yılda 101.88% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 50.6% oranında arttı

Analistler hisse senedi fiyatının 91.2% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl sulandırıldı

Ocumension Therapeutics Rakipler

YiChang HEC ChangJiang Pharmaceutical

SEHK:1558

HK$8.2b

China Shineway Pharmaceutical Group

SEHK:2877

HK$6.1b

Tong Ren Tang Technologies

SEHK:1666

HK$6.4b

Consun Pharmaceutical Group

SEHK:1681

HK$6.8b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Ocumension Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$5.19
52 Haftanın En Yüksek Seviyesi	HK$7.54
52 Haftanın En Düşük Seviyesi	HK$4.13
Beta	0.80
11 Aylık Değişim	-8.95%
3 Aylık Değişim	-2.99%
1 Yıllık Değişim	-28.02%
33 Yıllık Değişim	-71.07%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-85.97%

Son Haberler & Güncellemeler

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

Recent updates

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Sep 21

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Aug 15

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Jun 13

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Apr 29

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Mar 14

Could The Ocumension Therapeutics (HKG:1477) Ownership Structure Tell Us Something Useful?

Jan 23

Hissedar Getirileri

	1477	HK Pharmaceuticals	HK Pazar
7D	1.8%	0.07%	-0.6%
1Y	-28.0%	-10.2%	9.6%

Getiri vs. Endüstri: 1477 geçen yıl % -10.2 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.

Getiri vs Piyasa: 1477 geçen yıl % 9.6 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 1477's price volatile compared to industry and market?
1477 volatility
1477 Average Weekly Movement	8.7%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	8.9%
10% most volatile stocks in HK Market	19.2%
10% least volatile stocks in HK Market	4.3%

İstikrarlı Hisse Senedi Fiyatı: 1477 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 1477 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2017	477	Victor Liu	www.ocumension.com

Ocumension Therapeutics, iştirakleri ile birlikte Çin Halk Cumhuriyeti'nde bir oftalmik ilaç platformu şirketi olarak faaliyet göstermektedir. Oftalmik hastalar için tedaviler keşfetmekte, geliştirmekte ve ticarileştirmektedir. Portföyünde kronik enfeksiyöz olmayan üveit, blefarit, enfektif ve alerjik konjonktivit, diyabetik maküler ödem, kuru göz, glokom ve oküler hipertansiyon, postoperatif enflamasyon, koroidal neovaskülarizasyon, bakteriyel konjonktivit, retinitis pigmentosa, akut glokom, yaşa bağlı maküler dejenerasyon, kornea greft reddi, miyopi ve optik nörit tedavisine yönelik ürünler ve ilaçlar bulunmaktadır.

Ocumension Therapeutics Temel Bilgiler Özeti

Ocumension Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1477 temel i̇stati̇sti̇kler
Piyasa değeri	HK$4.24b
Kazançlar(TTM)	-HK$346.72m
Gelir(TTM)	HK$333.37m

12.7x

P/S Oranı

-12.2x

F/K Oranı

1477 aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1477 gelir tablosu (TTM)
Gelir	CN¥310.29m
Gelir Maliyeti	CN¥129.44m
Brüt Kâr	CN¥180.86m
Diğer Giderler	CN¥503.58m
Kazançlar	-CN¥322.73m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.39
Brüt Marj	58.29%
Net Kâr Marjı	-104.01%
Borç/Özkaynak Oranı	0%

1477 uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

1477 Stoklara Genel Bakış

Ödüller

Risk Analizi

Ocumension Therapeutics Rakipler

SEHK:1558

HK$8.2b

SEHK:2877

HK$6.1b

SEHK:1666

HK$6.4b

SEHK:1681

HK$6.8b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

Recent updates

Ocumension Therapeutics Announces Resignation of Yumeng Wang as Non-Executive Director

New minor risk - Shareholder dilution

Ocumension Therapeutics Announces New Drug Application of OT-502 Accepted by the National Medical Products Administration

With Ocumension Therapeutics (HKG:1477) It Looks Like You'll Get What You Pay For

Ocumension Therapeutics Announces New Drug Application of OT-1001 Approved by the National Medical Products Administration

Analysts Are Upgrading Ocumension Therapeutics (HKG:1477) After Its Latest Results

New minor risk - Profitability

First half 2024 earnings released: CN¥0.23 loss per share (vs CN¥0.32 loss in 1H 2023)

Ocumension Therapeutics to Report First Half, 2024 Results on Aug 12, 2024

Ocumension Therapeutics Announces Biologic License Application for OT-702 Accepted by the National Medical Products Administration

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Ocumension Therapeutics' (HKG:1477) CEO For Now

Ocumension Therapeutics, Annual General Meeting, Jun 20, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics' (HKG:1477) P/S Still Appears To Be Reasonable

Consensus revenue estimates decrease by 14%, EPS upgraded

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Ocumension Therapeutics Announces Phase II Clinical Trial of OT-202

Here's Why We're Not Too Worried About Ocumension Therapeutics' (HKG:1477) Cash Burn Situation

Ocumension Therapeutics to Report Fiscal Year 2023 Results on Mar 21, 2024

Ocumension Therapeutics (SEHK:1477) commences an Equity Buyback for 69,071,128 shares, representing 10% of its issued share capital, under the authorization approved on June 16, 2023.

Ocumension Therapeutics Completes Enrollment in the Phase Iii Clinical Trial of OT-502 in China

Ocumension Therapeutics Completes Patient Enrollment in the Phase II Clinical Trial of OT-202 in China

Ocumension Therapeutics Announces Executive Changes, Effective September 30, 2023

Consensus revenue estimates decrease by 13%

Consensus revenue estimates fall by 27%

Some Analysts Just Cut Their Ocumension Therapeutics (HKG:1477) Estimates

New minor risk - Profitability

First half 2023 earnings released: CN¥0.32 loss per share (vs CN¥0.31 loss in 1H 2022)

Ocumension Therapeutics to Report First Half, 2023 Results on Aug 24, 2023

Ocumension Therapeutics Announces Clinical Trial Authorization for Initiating A Phase III Clinical Trial of Ot-101-S

We're Hopeful That Ocumension Therapeutics (HKG:1477) Will Use Its Cash Wisely

Forecast to breakeven in 2025

Ocumension Therapeutics Completes Patient Enrollment in Globalmulti-Center Phase III Clinical Trial of OT-101

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS and revenues miss analyst expectations

Ocumension Therapeutics Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended December 31, 2022

No longer forecast to breakeven

Ocumension Therapeutics Provides Update on Phase I Clinical Trial of Ot-202

Ocumension Therapeutics Announces Patient Enrollment Complete in the Phase III Clinical Trial of OT-101 in China

Now 22% undervalued

Now 22% undervalued after recent price drop

Less than half of directors are independent

Board Member exercised options and sold HK$558k worth of stock

Consensus forecasts updated

First half 2022 earnings released: CN¥0.31 loss per share (vs CN¥0.12 loss in 1H 2021)

Ocumension Therapeutics to Report First Half, 2022 Results on Aug 26, 2022

Board Member recently sold HK$246k worth of stock

Now 24% undervalued

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for Yutio Chronic Non-Infectious Uveitis

EyePoint Pharmaceuticals, Inc. and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ(R) for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye

Ocumension Therapeutics Announces Executive Changes

Ocumension Therapeutics Announces CDE Approval Received for A Phase III Clinical Trial of OT-703 in China

Ocumension Therapeutics Receives Approval from the National Medical Products Administration for its IND Application to Begin the Phase Iii Clinical Study for Fluocinolone Acetonide Intravitreal Implant

Is Ocumension Therapeutics (HKG:1477) Trading At A 48% Discount?

Less than half of directors are independent

Ocumension Therapeutics Appoints Mr. Zhenyu Zhang as Independent Non-Executive Director, the Chairman of the Remuneration Committee and a Member of the Nomination Committee and Audit Committee

Ocumension Therapeutics Announces Demise of Lianming HE, Independent Non-Executive Director, Chairman of the Remuneration Committee and Member of the Audit Committee and Nomination Committee

Consensus forecasts updated

Forecast to breakeven in 2024